Zhisheng Wei1, Xuemei Deng2, Mingfan Hong1, Quanxi Su1, Aiqun Liu1, Yeqing Huang1, Qingyun Yu1, Zhongxing Peng1. 1. Department of Neurology, School of Clinical Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University No. 19 Nonglinxia Road, Guangzhou 510080, People's Republic of China. 2. Department of Neurology, The Third Hospital of Wuhan No. 241 Peng Liuyang Road, Wuhan 430060, People's Republic of China.
Abstract
BACKGROUND: High-dose methylprednisolone (MP) is a clinically recommended therapeutic regimen for Multiple Sclerosis (MS), whereas some dreadful complications induced by it remain inevitable. Studies implied that estrogens might play neuroprotective and anti-inflammatory roles in EAE and MS and promote glucocorticoid efficacy. Icariin (ICA), a primary active component of Epimedium extracts, also possesses neuroprotective and estrogen-like effects with less adverse complication than estrogen. However, rare study focuses ICA's effects on MS or EAE. OBJECTIVE: Our purpose is to determine whether ICA has synergistic effects with MP in treating EAE and explore the possible mechanisms. METHODS: C57BL/6 EAE mice were received different dose of ICA combined with MP and single MP treatment. Then, the clinical scores and serum Interleukin-17 (IL-17), Corticosterone (CORT), Adrenocorticotropic Hormone (ACTH) concentrations were analyzed. Western blot and Flow Cytometry were used to investigate the expression of glucocorticoid receptor (GR) and cell apoptosis. RESULTS: ICA has cooperative effects with MP in decreasing serum IL-17 and CORT concentrations, up-regulating the expression of GR in cerebral white matter and attenuating the cell apoptosis in spinal cord, especially high-dose ICA combined with MP. CONCLUSION: ICA has synergistic effects with MP to ameliorate EAE via modulating hypothalamic-pituitary-adrenal (HPA) function, promoting anti-inflammatory and anti-apoptotic effects. ICA could be considered as a promising therapeutic option for MS.
BACKGROUND: High-dose methylprednisolone (MP) is a clinically recommended therapeutic regimen for Multiple Sclerosis (MS), whereas some dreadful complications induced by it remain inevitable. Studies implied that estrogens might play neuroprotective and anti-inflammatory roles in EAE and MS and promote glucocorticoid efficacy. Icariin (ICA), a primary active component of Epimedium extracts, also possesses neuroprotective and estrogen-like effects with less adverse complication than estrogen. However, rare study focuses ICA's effects on MS or EAE. OBJECTIVE: Our purpose is to determine whether ICA has synergistic effects with MP in treating EAE and explore the possible mechanisms. METHODS: C57BL/6 EAE mice were received different dose of ICA combined with MP and single MP treatment. Then, the clinical scores and serum Interleukin-17 (IL-17), Corticosterone (CORT), Adrenocorticotropic Hormone (ACTH) concentrations were analyzed. Western blot and Flow Cytometry were used to investigate the expression of glucocorticoid receptor (GR) and cell apoptosis. RESULTS:ICA has cooperative effects with MP in decreasing serum IL-17 and CORT concentrations, up-regulating the expression of GR in cerebral white matter and attenuating the cell apoptosis in spinal cord, especially high-dose ICA combined with MP. CONCLUSION:ICA has synergistic effects with MP to ameliorate EAE via modulating hypothalamic-pituitary-adrenal (HPA) function, promoting anti-inflammatory and anti-apoptotic effects. ICA could be considered as a promising therapeutic option for MS.
Authors: F Sellebjerg; D Barnes; G Filippini; R Midgard; X Montalban; P Rieckmann; K Selmaj; L H Visser; P S Sørensen Journal: Eur J Neurol Date: 2005-12 Impact factor: 6.089
Authors: Jeroen Melief; Stella J de Wit; Corbert G van Eden; Charlotte Teunissen; Jörg Hamann; Bernard M Uitdehaag; Dick Swaab; Inge Huitinga Journal: Acta Neuropathol Date: 2013-06-28 Impact factor: 17.088
Authors: Hong Yan Liu; Abigail C Buenafe; Agata Matejuk; Atsushi Ito; Alex Zamora; Jami Dwyer; Arthur A Vandenbark; Halina Offner Journal: J Neurosci Res Date: 2002-10-15 Impact factor: 4.164